SOT-075

SOT-075 is an investigational antibody-drug conjugate (ADC) being developed by SOTIO Biotech. It is designed to target a specific tumor-associated antigen, though the exact target has not been publicly disclosed in detail in early pipeline communications. The molecule typically consists of a monoclonal antibody conjugated to a potent cytotoxic payload via a linker, intended to deliver the toxin directly to cancer cells while minimizing systemic toxicity. As of early 2024, the program is in the preclinical stage of development, part of SOTIO's broader strategy to expand its ADC portfolio alongside other candidates like SOT102.